Randomized Trial of Tacrolimus Monotherapy: Tacrolimus In Combination, Tacrolimus Alone Compared (The TICTAC Trial)

Baran, David A.; Zucker, Mark; Arroyo, Luis H.; Alwarshetty, Mamata; Ramirez, Maria Rosana; Prendergast, Thomas; Goldstein, Daniel J.; Camacho, M.; Gass, Alan; Carr, C.; Cohen, Marc

doi:10.1016/j.healun.2007.07.022

Cited by 30 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, in this study, the success rate was 97% among patients with zero or one HLA‐DR mismatch. More recently, corticosteroid withdrawal was achieved as early as 8‐12 weeks after transplant in a trial comparing tacrolimus alone with tacrolimus in combination with MMF after transplantation, with comparable cellular rejection rates at 6 and 12 months …”

Section: Discussionmentioning

confidence: 99%

Corticosteroid wean after heart transplantation—Is there a risk for antibody formation?

Elboudwarej

Phan

Patel

et al. 2017

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Corticosteroid wean after heart transplantation—Is there a risk for antibody formation?

Elboudwarej

Phan

Patel

et al. 2017

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…Recommendations for the Minimization of Immunosuppression: 159,162,188,[232][233][234][235][236][237][238][239][240][241][242] Class I:…”

Section: Topic 1: Minimization Of Immunosuppressionmentioning

confidence: 99%

The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients

Costanzo¹,

Dipchand²,

Starling³

et al. 2010

The Journal of Heart and Lung Transplantation

1,459

1,105

View full text Add to dashboard Cite

“…However, tacrolimus has been shown to be associated with a lower incidence of hyperlipidaemia and hypertension with no difference in hyperglycaemia, renal function or incidence of infection when compared to cyclosporine [25]. It has also been suggested that tacrolimus monotherapy in heart transplant recipients is safe and efficacious and is not associated with increased high-grade rejection or CTV [26,27]. …”

Section: Discussionmentioning

confidence: 99%

Myocardial infarction in an adult with cystic fibrosis and heart and lung transplant

Eaden

Peckham

2013

Multidiscip Respir Med

View full text Add to dashboard Cite

We present a case of myocardial infarction in a 19 year old female with cystic fibrosis who had a heart and lung transplant performed at the age of four years old. She presented atypically with a one day history of severe, intermittent, central, sharp chest pain, radiating to her back and down her left arm. A coronary angiogram showed proximal stenosis of the left anterior descending artery and right coronary artery. She was treated with percutaneous coronary intervention, involving drug eluting stents to the left anterior descending artery (LAD) and the right coronary artery (RCA). In this study we discuss the pathophysiology, investigations and treatment of cardiac transplant vasculopathy. Although complete reversal of LAD and RCA stenosis was achieved, routine follow-up with coronary angiography and careful control of cardiac risk factors will be important to identify and reduce future restenosis and adverse cardiac events.

show abstract

Randomized Trial of Tacrolimus Monotherapy: Tacrolimus In Combination, Tacrolimus Alone Compared (The TICTAC Trial)

Cited by 30 publications

References 18 publications

Corticosteroid wean after heart transplantation—Is there a risk for antibody formation?

Corticosteroid wean after heart transplantation—Is there a risk for antibody formation?

The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients

Myocardial infarction in an adult with cystic fibrosis and heart and lung transplant

Contact Info

Product

Resources

About